Effect of ranolazine on the course of ischemic heart disease after percutaneous coronary intervention
Optimization of antiischemic therapy is necessary in many patients with stable forms of coronary heart disease after or during revascularization. From the standpoint of current guidelines, the addition of second-line drugs, in particular ranolazine, to beta-blockers and/or calcium antagonists is con...
Main Authors: | О.А. Yepanchintseva, O.J. Zharinov, І.V. Shklianka |
---|---|
Format: | Article |
Language: | English |
Published: |
TOV Chetverta Khvylia
2020-12-01
|
Series: | Кардіохірургія та інтервенційна кардіологія |
Subjects: | |
Online Access: | http://www.csic.com.ua/images/pdf/2020/4-2020/effect-ranolazine-course-ischemic-heart-disease-after-percutaneous-coronary-intervention.pdf |
Similar Items
-
Association between Ranolazine, Ischemic Preconditioning, and Cardioprotection in Patients Undergoing Scheduled Percutaneous Coronary Intervention
by: Konstantinos Kourtis, et al.
Published: (2024-01-01) -
RANOLAZINE IN ISCHEMIC HEART DISEASE
by: V. P. Lupanov
Published: (2015-12-01) -
The use of ranolazine in the treatment of coronary heart disease
by: V. S Zadionchenko, et al.
Published: (2014-12-01) -
Ranolazine: Multifaceted role beyond coronary artery disease, a recent perspective
by: Gopal Chandra Ghosh, et al.
Published: (2018-01-01) -
Ranolazine as an additional antianginal therapy in patients with stable symptomatic coronary artery disease
by: Benjamín Sanfuentes, et al.
Published: (2018-11-01)